Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually

September 22, 2020Filed Under: NewsBy admin

“The report finds that extending patents on just those five drugs [Prilosec, TriCor, Suboxone, Doryx, and Namenda] will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”

Brand-name Drugmaker Tactic ‘Product Hopping’ Costs US Healthcare System $4.7 Billion Annually, Study Says

September 15, 2020Filed Under: NewsBy admin

“An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.”

New Report Shows Brand Drug Product Hopping Costs Billions for Patients and Healthcare System Each Year

September 14, 2020Filed Under: Press ReleasesBy admin

Report details five instances of product hopping that collectively cost $4.7 billion annually.

New MGA Paper Investigates the Economic and Budgetary Effects of the BLOCKING Act

January 13, 2020Filed Under: AnalysisBy admin

This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.